Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo reports positive results from Phase IIb constipation trial
The study has demonstrated a statistically significant increase in mean change in spontaneous bowel movements (SBM) from baseline after one week on treatment (p
The study has demonstrated a statistically significant increase in mean change in spontaneous bowel movements (SBM) from baseline after one week on treatment (p
Findings demonstrated that more than 80% of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years. The majority of
Results from the first study (Study 201), a Phase IIa dose-escalation trial involving 28 patients, demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall
Ms Pecota has previously served as CFO for NuGEN Technologies, a life sciences tools company. Prior to that Ms Pecota served as a financial consultant to early- and
The first patent covers laser tips that can be configured to direct energy in multiple directions including to the sides, away from the handpiece. This patent relates not
Dr Bostian joins Kemin from Mpex Pharmaceuticals, where he served as chief scientific officer and innovator of the company’s R&D platform. Dr Bostian is expected to add significant
The sub-group analysis was designed to determine whether interrupting Humira treatment would affect efficacy in psoriasis patients who had already achieved good response to Humira. After 33 weeks,
The European Commission’s decision was adopted following the favorable opinion issued by the European Medicine Agency Committee of Orphan Medicinal Products. The designation was granted to Triskel EU
Promius Pharma, which will initially focus on the branded dermatology market, is said to be based on a platform of strategic licensing initiatives and internal product development activities
The agreement is for the development of a marketed protein to be delivered using Flamel’s Medusa technology. Flamel is also receiving additional revenues from Wyeth for work being